72
Participants
Start Date
May 27, 2016
Primary Completion Date
March 31, 2019
Study Completion Date
April 9, 2019
AK0529
AK0529 is a novel compound being developed for the treatment of RSV infection. The enteric coated drug pellets with sugar core can be administered orally with apple sauce/purée or yoghurt, or by flushing with 10% dextrose water via a nasogastric or other feeding tube, or upon a glucose wafer.
Placebo
The placebo was made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed primarily of microcrystaline cellulose pellet.
Lady Cilento Children's Hospital, South Brisbane
Gold Coast University Hospital, Gold Coast
Women's and Children's Hospital, Adelaide
Prince of Wales Hospital, Shatin
Soroka University Medical Center, Beersheba
Ruth Rappaport Children's Hospital, Haifa
Schneider Children's Medical Center, Petach Tikvah
American University of Beirut Medical Center, Beirut
Makassed General Hospital, Beirut
Rafik Hariri University Hospital, Beirut
Saint George Hospital University Medical Center, Beirut
Hospital Tuanku Jaafar, Seremban
Hospital Sibu, Sibu
Hospital Selayang, Batu Caves
Hospital Tengku Ampuan Rahimah, Klang
University Malaya Medical Center, Kuala Lumpur
Specjalistyczny Zespół Opieki Zdrowotnej nad Matką i Dzieckiem w Poznaniu, Poznan
Nowy Szpital w Świeciu, Gmina Świecie
Szpital im. Świętej Jadwigi Śląskiej w Trzebnicy, Trzebnica
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City
Mackay Memorial Hospital, Taipei
National Taiwan University Hospital, Taipei
Taipei Municipal Wanfang Hospital, Taipei
Linkou Chang Gung Memorial Hospital, Taoyuan District
Cukurova University Balcali Hospital, Adana
Eskisehir Osmangazi University Faculty of Medicine, Eskişehir
Ege University Medical Faculty, Izmir
Marmara University Faculty of Medicine, Istanbul
Collaborators (1)
Ark Biosciences Pty Ltd.
UNKNOWN
Shanghai Ark Biopharmaceutical Co., Ltd.
INDUSTRY